Tango Therapeutics (TNGX) Operating Expenses (2020 - 2026)

Tango Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $48.8 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 452.56% year-over-year to $48.8 million; the TTM figure through Mar 2026 stood at $248.5 million (up 6.75% YoY), while the FY2025 annual figure was $173.7 million, down 7.46% from the prior year.
• Operating Expenses was $48.8 million for Q1 2026 at Tango Therapeutics, down from $148.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $167.1 million in Q4 2024 to a low of $7.1 million in Q3 2025.
• Historically, Operating Expenses has averaged $48.0 million across 5 years, with a median of $37.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses slumped 81.89% in 2025, then surged 452.56% in 2026.
• A 5-year view of Operating Expenses shows it stood at $37.0 million in 2022, then rose by 9.37% to $40.4 million in 2023, then surged by 313.07% to $167.1 million in 2024, then declined by 11.11% to $148.5 million in 2025, then slumped by 67.16% to $48.8 million in 2026.
• The last three Operating Expenses figures came in at $48.8 million (Q1 2026), $148.5 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.